Literature DB >> 21600605

Intravenous sildenafil as a preconditioning drug against hemodynamic consequences of warm ischemia-reperfusion on the kidney.

Enrique Lledo-Garcia1, David Subira-Rios, Gabriel Ogaya-Pinies, Alberto Tejedor-Jorge, Juan Francisco Del Cañizo-Lopez, Carlos Hernandez-Fernandez.   

Abstract

PURPOSE: We designed an experimental model of renal ischemia-reperfusion to evaluate the preemptive effect of intravenous sildenafil according to the dose administered (0.7 vs 1.4 mg/kg) and the time of administration (30 minutes before ischemia or during ischemia).
MATERIALS AND METHODS: A total of 20 minipigs were divided into groups of 4 each, including group 1-control, group 2-sildenafil 0.7 mg/kg intravenously 30 minutes before vascular clamping, group 3-sildenafil 0.7 mg/kg intravenously during warm ischemia, group 4-sildenafil 1.4 mg/kg intravenously 30 minutes before vascular clamping and group 5-sildenafil 1.4 mg/kg intravenously during warm ischemia. The ischemia-reperfusion model was applied using laparotomy and right kidney vascular clamping for 30 minutes, followed by unclamping and reperfusion for 45 minutes. Renal vascular flow and systemic mean arterial pressure were recorded for 45 minutes after unclamping. Mean values were compared using Student t test with significance considered at p <0.05.
RESULTS: Sildenafil led to a decrease in arterial pressure compared to that in controls, especially at the dose of 1.4 vs 0.7 mg/kg, including 113.77, 109.76, 106.12, 97.41 and 82.85 mm Hg in groups 1 to 5, respectively. Renal vascular flow was significantly higher in groups 2 and 3 than in groups 1, 4 and 5 (112.82 and 111.33 vs 88.25, 87.91 and 84.37 ml per minute, respectively, p = 0.000).
CONCLUSIONS: The effect of intravenous sildenafil as a preemptive drug against the hemodynamic effects of renal ischemia-reperfusion is dose dependent. The 0.7 mg/kg dose significantly increased reperfusion renal vascular flow with a small decrease in arterial pressure compared to the 1.4 mg/kg dose.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600605     DOI: 10.1016/j.juro.2011.03.036

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats.

Authors:  A Küçük; M Yucel; N Erkasap; M Tosun; T Koken; M Ozkurt; S Erkasap
Journal:  Mol Biol Rep       Date:  2012-06-27       Impact factor: 2.316

Review 2.  Phosphodiesterase type 5 inhibitors and kidney disease.

Authors:  Baris Afsar; Alberto Ortiz; Adrian Covic; Abduzhappar Gaipov; Tarik Esen; David Goldsmith; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-08-05       Impact factor: 2.370

3.  Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury.

Authors:  D Adam Lauver; E Grant Carey; Ingrid L Bergin; Benedict R Lucchesi; Hitinder S Gurm
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

4.  Experimental isolation and preservation of solid organs before transplantation: effects of pretreatment using four different molecules.

Authors:  Maria Chalasti; Christos Iordanou; Zisis Kratiras; Aikaterini Stylianaki; Eleni-Andriana Trigka; Eleftheria Lakiotaki; Kali Makedou; Stavros Iliadis; Konstantinos G Zografos; Dimitrios Dimitroulis; Michail Chrisofos; Efstratios Patsouris; Georgios C Zografos; George C Bouboulis; Apostolos E Papalois
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

5.  Carbon monoxide-releasing molecule-3: Amelioration of renal ischemia reperfusion injury in a rat model.

Authors:  Dae Keun Kim; Su-Jin Shin; Jiyoung Lee; Sung Yul Park; Yong Tae Kim; Hong Yong Choi; Young Eun Yoon; Hong Sang Moon
Journal:  Investig Clin Urol       Date:  2020-06-01

Review 6.  Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.

Authors:  Georgios Georgiadis; Ioannis-Erineos Zisis; Anca Oana Docea; Konstantinos Tsarouhas; Irene Fragkiadoulaki; Charalampos Mavridis; Markos Karavitakis; Stavros Stratakis; Kostas Stylianou; Christina Tsitsimpikou; Daniela Calina; Nikolaos Sofikitis; Aristidis Tsatsakis; Charalampos Mamoulakis
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.